Drugs / I-124 PGN650
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01632696 | Jun 2012 → May 2016 | cancer | Peregrine Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I-124 PGN650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01632696 ↗ |
| Route | Intravenous | “single intravenous (IV) dose” NCT01632696 ↗ |